» Articles » PMID: 25212258

Observational Studies of the Association Between Glucose-lowering Medications and Cardiovascular Outcomes: Addressing Methodological Limitations

Overview
Journal Diabetologia
Specialty Endocrinology
Date 2014 Sep 13
PMID 25212258
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recent years have witnessed a growing body of observational literature on the association between glucose-lowering treatments and cardiovascular disease. However, many of the studies are based on designs or analyses that inadequately address the methodological challenges involved.

Methods: We reviewed recent observational literature on the association between glucose-lowering medications and cardiovascular outcomes and assessed the design and analysis methods used, with a focus on their ability to address specific methodological challenges. We describe and illustrate these methodological issues and their impact on observed associations, providing examples from the reviewed literature. We suggest approaches that may be employed to manage these methodological challenges.

Results: From the evaluation of 81 publications of observational investigations assessing the association between glucose-lowering treatments and cardiovascular outcomes, we identified the following methodological challenges: 1) handling of temporality in administrative databases; 2) handling of risks that vary with time and treatment duration; 3) definitions of the exposure risk window; 4) handling of exposures that change over time; and 5) handling of confounding by indication. Most of these methodological challenges may be suitably addressed through application of appropriate methods.

Conclusions/interpretation: Observational research plays an increasingly important role in the evaluation of the clinical effects of diabetes treatment. Implementation of appropriate research methods holds the promise of reducing the potential for spurious findings and the risk that the spurious findings will mislead the medical community about risks and benefits of diabetes medications.

Citing Articles

Ibuprofen, other NSAIDs and COVID-19: a narrative review.

Laughey W, Lodhi I, Pennick G, Smart L, Sanni O, Sandhu S Inflammopharmacology. 2023; 31(5):2147-2159.

PMID: 37603158 PMC: 10518289. DOI: 10.1007/s10787-023-01309-7.


Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark.

Thomsen R, Christensen L, Kahlert J, Knudsen J, Ustyugova A, Sandgaard S Diabetes Ther. 2022; 13(11-12):1891-1906.

PMID: 36315384 PMC: 9663772. DOI: 10.1007/s13300-022-01323-y.


Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions.

Wang S, Sreedhara S, Schneeweiss S Nat Commun. 2022; 13(1):5126.

PMID: 36045130 PMC: 9430007. DOI: 10.1038/s41467-022-32310-3.


Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes.

Shin H, Schneeweiss S, Glynn R, Patorno E Pharmacoepidemiol Drug Saf. 2022; 31(5):566-576.

PMID: 34985178 PMC: 8989653. DOI: 10.1002/pds.5406.


Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study.

Zerovnik S, Kos M, Locatelli I BMJ Open. 2021; 11(9):e051549.

PMID: 34518273 PMC: 8438902. DOI: 10.1136/bmjopen-2021-051549.


References
1.
Masoudi F, Inzucchi S, Wang Y, Havranek E, Foody J, Krumholz H . Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005; 111(5):583-90. DOI: 10.1161/01.CIR.0000154542.13412.B1. View

2.
Toprani A, Fonseca V . Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes. Diabetes Obes Metab. 2011; 13(3):276-80. DOI: 10.1111/j.1463-1326.2010.01348.x. View

3.
Anselmino M, Ohrvik J, Malmberg K, Standl E, Ryden L . Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J. 2007; 29(2):177-84. DOI: 10.1093/eurheartj/ehm519. View

4.
Morgan C, Poole C, Evans M, Barnett A, Jenkins-Jones S, Currie C . What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab. 2012; 97(12):4605-12. DOI: 10.1210/jc.2012-3034. View

5.
Renehan A, Yeh H, Johnson J, Wild S, Gale E, Moller H . Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia. 2012; 55(6):1619-32. DOI: 10.1007/s00125-012-2526-0. View